Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%

Main Article Content

Linda Stein Gold
Jonathan S Weiss
Lawrence Green
Leon Kircik
Lauren Miller
Abby Jacobson
Susan Harris


Psoriasis, Corticosteroid, Halobetasol, Tazarotene, Retinoid


Abstract not available.


1. Weigle N, et al. Am Fam Physician. 2013;87(9):626-633.

2. Torsekar R, et al. Indian Dermatol Online J. 2017;8(4):235-245.

3. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.

4. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>